Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certoparin in Persistent Nonvalvular Atrial Fibrillation
NCT00171769Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of certoparin in persistent atrial fibrillation (PersAF), sponsored by Novartis. Primary endpoint: Safety measures including reporting of serious adverse events and adverse events. Started Apr 2005; status: completed.
02
Drugs
certoparin
03
Conditions
persistent atrial fibrillation (PersAF)
Beyond the preview
Go deeper on NCT00171769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171769.